AI Robots: Trading in Every Style
Eli Lilly & Co (LLY) experienced a significant surge in market capitalization last week, recording an impressive increase of $51.0 billion. This surge in market cap propelled the company's stock price to $431.19. The 14.6% jump in market cap marked Eli Lilly & Co as the leader in terms of market cap growth among 57 stocks analyzed in the Pharmaceuticals: Major Industry by A.I.dvisor for the week ending May 3, 2023.
AI analysis revealed that out of the 57 stocks in the Pharmaceuticals: Major Industry, 34 of them, accounting for 58.82%, were in an uptrend. This indicates positive performance and upward momentum in the industry. On the other hand, 23 stocks, representing 41.18% of the total, were observed to be in a downtrend, suggesting a decline in their market performance.
Eli Lilly & Co's impressive market cap increase not only showcases its strong performance but also reflects investors' confidence in the company's future prospects. This surge in market cap indicates a favorable market sentiment towards Eli Lilly & Co and its position within the pharmaceutical industry.
Investors and stakeholders will closely monitor Eli Lilly & Co's performance in the coming weeks to gauge the sustainability of this growth. Furthermore, the overall trend in the Pharmaceuticals: Major Industry will also be a point of interest as market dynamics continue to evolve.
LLY's Aroon Indicator triggered a bullish signal on March 13, 2024. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 329 similar instances where the Aroon Indicator showed a similar pattern. In of the 329 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on March 22, 2024. You may want to consider a long position or call options on LLY as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in of 357 cases, the price rose further within the following month. The odds of a continued upward trend are .
LLY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for LLY moved out of overbought territory on March 05, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on February 27, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LLY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (68.493) is very high in comparison to the industry average of (5.792). P/E Ratio (134.169) is within average values for comparable stocks, (49.793). Projected Growth (PEG Ratio) (1.473) is also within normal values, averaging (3.057). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.029). LLY's P/S Ratio (20.619) is very high in comparison to the industry average of (3.723).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor